CANCER MARKER AND CANCER DETERMINATION METHOD
The invention relates to a cancer marker, consisting of a portion of or all of the nucleotide sequence represented by SEQ ID NO: 1 in a FOXB2 gene derived from a cell, and being continuous nucleotide sequences comprising at least the nucleotide sequence represented by SEQ ID NO: 2 or 3, wherein 30% or more of cytosines of the -CG- sequences present in said nucleotide sequence are methylated, and method for determining canceration of a cell on the basis of methylation ratio, wherein said methylation ratio is measured by a bisulfate reaction for a portion of or all of cytosines of the -CG- sequences present in the nucleotide sequence represented by SEQ ID NO: 1 in a FOXB2 gene derived from a cell.
1 . A cancer marker consisting of a portion of or all of the nucleotide sequence represented by SEQ ID NO: 1 in a FOXB2 gene derived from a cell, and being continuous nucleotide sequences comprising at least the nucleotide sequence represented by SEQ ID NO: 3, wherein 30% or more of cytosines of the -CG- sequences present in said nucleotide sequence are methylated.
2 . The cancer marker according to claim 1 consisting of the nucleotide sequence represented by SEQ ID NO: 3 in the FOXB2 gene derived from a cell, wherein 40% or more of cytosines of the -CG- sequences present in said nucleotide sequence are methylated.
3 . A cancer marker consisting of a portion of or all of the nucleotide sequence represented by SEQ ID NO: 1 in a FOXB2 gene derived from a cell, and being continuous nucleotide sequences comprising at least the nucleotide sequence represented by SEQ ID NO: 2, wherein 30% or more of cytosines of the -CG- sequences present in said nucleotide sequence are methylated.
4 . The cancer marker according to claim 3 consisting of the nucleotide sequence represented by SEQ ID NO: 2 in the FOXB2 gene derived from a cell, wherein 40% or more of cytosines of the -CG- sequences present in said nucleotide sequence are methylated.
5 . A method for determining canceration of cells, wherein methylation ratio for a portion of or all of cytosines of the -CG- sequences present in the nucleotide sequence represented by SEQ ID NO: 1 in a FOXB2 gene derived from a cell, is measured by a bisulfate reaction, and canceration of the cell is determined on the basis of methylation ratio.
6 . The method according to claim 5 , wherein when methylation ratio is 30% or more, the cell is determined to be cancerous.
7 . The method according to claim 5 , wherein methylation ratio of all of cytosines of the -CG- sequences at least in the nucleotide sequence represented by SEQ ID NO: 3, is measured.
8 . The method according to claim 7 , wherein when methylation ratio is 40% or more, the cell is determined to be cancerous.
9 . The method according to claim 5 , wherein methylation ratio of all of cytosines of the -CG- sequences at least in the nucleotide sequence represented by SEQ ID NO: 2, is measured.
10 . The method according to claim 9 , wherein when methylation ratio is 40% or more, the cell is determined to be cancerous.